Yong, Dongeun http://orcid.org/0000-0002-1225-8477
Lee, Hakbae http://orcid.org/0000-0002-4615-2646
Min, Hyung-Gyu http://orcid.org/0000-0002-7944-6130
Kim, Kyungnam http://orcid.org/0000-0002-4889-3069
Oh, Hyun-Seok http://orcid.org/0000-0001-8560-7132
Chu, Min Kyung http://orcid.org/0000-0001-6221-1346
Funding for this research was provided by:
National Research Foundation of Korea (2022R1A2C1091767)
Article History
Received: 28 February 2022
Accepted: 4 January 2023
First Online: 12 January 2023
Competing interests
: Author MKC was a site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and the Ildong Pharmaceutical Company. He has received lecture honoraria from Eli Lilly and Company, Handok-Teva, and Ildong Pharmaceutical Company over the past 36 months. He received grants from Yonsei University College of Medicine (6–2021-0229), the Korea Health Industry Development Institute (KHIDI) (HV22CO106) and National Research Foundation of Korea (2022R1A2C1091767). Author HSO is employed by CJ Bioscience Inc. The other authors declare that they have no competing interests.